Association of K-ras Mutational Status a
β
Daniel J. Freeman; Todd Juan; Maureen Reiner; J. Randolph Hecht; Neal J. Meropol
π
Article
π
2008
π
CIG Media Group, LP.
π
English
β 502 KB
Background: Identifying predictive biomarkers is important to optimally treat patients. This analysis evaluated the association of K-ras, BRAF, and PIK3CA gene mutations with tumor resistance to panitumumab alone. Patients and Methods: From 3 phase II panitumumab metastatic colorectal cancer (mCRC)